At present, the success of immunotherapy for melanoma appears to depend on enhancing melanoma-specific CD8+ T cell immunity since CD8+ T cells are strongly associated with direct tumor killing and a melanoma patient’s survival. The gene discussed is CD8A; the disease is melanoma.